市場調查報告書
商品編碼
1433394
全球皮膚切片市場 2023-2030Global Skin Biopsy Market 2023-2030 |
預計在預測期內(2023-2030年),全球皮膚切片市場將以6.8%的複合CAGR成長。市場的成長歸因於對先進護膚產品的需求。消費者對高品質護膚產品的需求持續成長,尤其是那些採用科學驗證的顯著成分(如透明質酸、胜肽和抗氧化劑)設計的產品。新產品的推出激發了護膚界的興趣和調查。例如,2022年12月,Hydrinity Accelerated Skin Science推出了新的臉部護膚系列,其中含有眾所周知的透明質酸(HA)成分、PPM技術以及多種胜肽和抗氧化劑。新的護膚系列包括更新的透明質酸精華液、保濕和修復精華液,以及輕盈、有益於微生物組的淨化噴霧,所有這些都目的是減少衰老跡象、改善膚質並加速皮膚癒合。然而,皮膚活體組織切片的高成本可能會限制其在低收入經濟體的成長。
全球皮膚切片市場依類型、適應症和最終用戶進行細分。根據類型,市場分為刮取活體組織切片、穿刺活體組織切片和切除活體組織切片。根據適應症,市場細分為皮膚癌診斷和分期、光化性角化病、皮膚炎等。此外,根據最終用戶,市場細分為醫院、診斷實驗室等。皮膚癌診斷和分期子類別預計將佔據適應症領域的很大一部分市場佔有率。這種成長可歸因於皮膚癌盛行率的增加,以及皮膚病的診斷較早。此外,皮膚癌需要盡快檢測和治療,以避免在危險的黑色素瘤或其他皮膚癌的情況下需要手術。
在最終用戶中,診斷實驗室細分市場預計將在全球皮膚活體組織切片市場中佔據相當大的佔有率。細分市場的成長歸功於創新的診斷方法。使用皮膚切片樣本診斷阿茲海默症是神經學領域的創新方法。這些創新方法拓寬了皮膚活體組織切片在皮膚科以外的應用,有助於皮膚活體組織切片行業的多元化。例如,2023年2月,SynapsDx準備推出基於皮膚的阿茲海默症診斷測試。 Synaps 使用三種生物標記來診斷阿茲海默症並將其與其他失智症類型區分開來。主要診斷基於形態測量成像,該成像測量患者皮膚樣本中成纖維細胞的細胞生長。阿茲海默症患者的大聚集體較少。
全球皮膚切片市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區),以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於皮膚健康意識的增強,預計亞太地區將在全球市場中佔據顯著佔有率,預計診斷和治療過程將在整個預測期內推動市場發展。
考慮到全球皮膚活體組織切片市場,北美保持不變
Global Skin Biopsy Market Size, Share &Trends Analysis Report by Type (Shave Biopsy, Punch Biopsy, and Excisional Biopsy), by Indication (Skin Cancer Diagnosis and Staging, Actinic keratosis, Dermatitis, and Others) and by End-User (Hospitals, Diagnostic Laboratories, and Others), Forecast Period (2023-2030)
The global skin biopsy market is anticipated to grow at a considerable CAGR of 6.8% during the forecast period (2023-2030).The market's growth is attributed to the demand for advanced skincare products. Consumer demand for high-quality skincare products, particularly those designed with prominent and scientifically validated components such as HA, peptides, and antioxidants, continues to rise. The launch of new products stimulates interest and investigation in the skincare sector. For instance, in December 2022, Hydrinity Accelerated Skin Science launched new facial skin care line with well-known ingredients of hyaluronic acid (HA), PPM technology, and numerous peptides and antioxidants. The new skin care line includes a renewing HA serum, a hydrating and healing serum, and a lightweight, microbiome-friendly purifying mist, all designed to reduce signs of aging, improve texture, and accelerate skin healing. However, the high cost of skin biopsy may restrain its growth in low-income economies.
The global skin biopsy market is segmented on the type, indication, and end-user. Based on the type, the market is sub-segmented into shave biopsy, punch biopsy, and excisional biopsy. Based on the indication, the market is sub-segmented into skin cancer diagnosis and staging, actinic keratosis, dermatitis, and others. Furthermore, on the basis of end-user, the market is sub-segmented into hospitals, diagnostic laboratories, and others. The skin cancer diagnosis and staging subcategory is expected to capture a significant portion of the market share within the indication segment. The growth can be attributed to the skin cancer prevalence is increasing, and skin diseases have been diagnosed earlier. In addition, skin cancer needs to be detected and treated as soon as possible to avoid the need for surgery in the case of a dangerous melanoma or other skin cancer.
Among the end-user, the diagnostic laboratories sub-segment is expected to hold a considerable share in the global Skin Biopsy market. The segmental growth is attributed to the innovative diagnostic approaches. The use of skin biopsy samples to diagnose Alzheimer's disease is an innovative method in neurology. Such innovative approaches broaden the applications of skin biopsies outside dermatology, helping to diversify the skin biopsy industry. For instance, in February 2023, SynapsDx Prepares Launched Skin-Based Alzheimer's Disease Diagnostic Test. Synaps uses three biomarkers to diagnose Alzheimer's disease and differentiate it from other dementia forms. The primary diagnosis is based on morphometric imaging, that measures cell growth in fibroblasts from a patient's skin sample. Alzheimer's patients have fewer large aggregates.
The global skin biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to increased awareness of skin health, diagnosis, and treatment processes is expected to drive the market throughout the forecast period.
The North America Holds Considering the global Skin Biopsy Market
Regional growth is attributed to the medical need for pediatric skin biopsies. The observations highlight the importance of skin biopsies in the diagnosis of pediatric skin disorders. As a result children and adolescents account for a sizable proportion of biopsy cases, the demand for biopsy equipment and services tailored to younger patients has the potential to drive market expansion.
According to the National Institute of Government, in June 2023, a study analyzed 1308 biopsy records, revealing a male predominance and a majority of patients were adolescents. Furthermore, study found that 12.9% of pediatric skin biopsies were performed, with 83.9% of patients underwent a single biopsy. The majority of patients underwent multiple biopsies, with 98% performing a biopsy for diagnostic purposes. The mean age of patients was 12 years, with males outnumbering females. The study emphasizes the importance of skin biopsies in pediatric patients and the high clinic-histopathologic agreement. Leprosy and papulosquamous diseases were the most common cases.
The major companies serving the skin biopsy market includes Cardinal Health Inc., AccTec Inc., Beckton, Dickenson, and Company, Bio-Rad Laboratories Inc., and Kai Group among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market.
For instance in June 2019,Proscia Launched DermAI to Pre-Screen and Classify Skin Biopsies. Proscia's AI-powered software can classify skin disease variants into pre-diagnostic categories, enhancing pathology confidence, quality, and speed, reducing errors and improving laboratory efficiency.